CBT profiles of cabozantinib approved for advanced renal cell carcinomas

被引：12
|
作者：
Wang, Xiangdong [1 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Inst Clin Sci, Shanghai Inst Clin Bioinformat, Shanghai, Peoples R China
来源：
CELL BIOLOGY AND TOXICOLOGY | 2016年 / 32卷 / 04期
关键词：
KINASE; INHIBITORS; MEDICINE; GROWTH;
D O I：
10.1007/s10565-016-9349-6
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：259 / 261
页数：3
相关论文
共 50 条
  • [41] SEQUENTIAL USAGE OF MTOR INHIBITOR FOLLOWED BY IMMUNOTHERAPIES FOR CABOZANTINIB-RESISTANT METASTATIC CLEAR CELL RENAL CELL CARCINOMAS
    Park, Jee Soo
    Lee, Myung Eun
    Jang, Won Sik
    Kim, Jongchan
    Park, Se Mi
    Ham, Won Sik
    JOURNAL OF UROLOGY, 2023, 209 : E725 - E726
  • [42] Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial
    Bilen, Mehmet A.
    Vo, BaoHan T.
    Liu, Yuan
    Greenwald, Rachel
    Davarpanah, Amir H.
    Mcguire, Donald
    Shiradkar, Rakesh
    Li, Liping
    Midya, Adhishek
    Nazha, Bassel
    Brown, Jacqueline T.
    Williams, Sierra
    Session, Wilena
    Russler, Greta
    Caulfield, Sarah
    Joshi, Shreyas S.
    Narayan, Vikram M.
    Filson, Christopher P.
    Ogan, Kenneth
    Kucuk, Omer
    Carthon, Bradley Curtis
    Del Balzo, Luke
    Cohen, Athena
    Boyanton, Adriana
    Prokhnevska, Nataliya
    Cardenas, Maria Andrea
    Sobierajska, Ewelina
    Jansen, Caroline S.
    Patil, Dattatraya H.
    Nicaise, Edouard
    Osunkoya, Adeboye O.
    Kissick, Haydn T.
    Master, Viraj A.
    NATURE CANCER, 2025, 6 (03) : 432 - 444
  • [43] Comparative Histological and Molecular Profiles of Clear Cell Renal Cell Carcinomas and Their Corresponding Metastases
    Dagher, Julien
    Kammerer-Jacquet, Solene-Florence
    Brunot, Angelique
    Lespagnol, Alexandra
    Jouan, Florence
    Lepage, Lorrie
    Cornevin, Laurence
    Dugay, Frederic
    Verhoest, Gregory
    Bensalah, Karim
    Belaud-Rotureau, Marc-Antoine
    Rioux-Leclercq, Nathalie
    LABORATORY INVESTIGATION, 2015, 95 : 214A - 214A
  • [44] Comparative Histological and Molecular Profiles of Clear Cell Renal Cell Carcinomas and Their Corresponding Metastases
    Dagher, Julien
    Kammerer-Jacquet, Solene-Florence
    Brunot, Angelique
    Lespagnol, Alexandra
    Jouan, Florence
    Lepage, Lorne
    Cornevin, Laurence
    Dugay, Frederic
    Verhoest, Gregory
    Bensalah, Karim
    Belaud-Rotureau, Marc-Antoine
    Rioux-Leclercq, Nathalie
    MODERN PATHOLOGY, 2015, 28 : 214A - 214A
  • [45] Cabozantinib in Patients with Advanced Merkel Cell Carcinoma
    Rabinowits, Guilherme
    Lezcano, Cecilia
    Catalano, Paul J.
    McHugh, Patricia
    Becker, Hailey
    Reilly, Megan M.
    Huang, Julian
    Tyagi, Ayushi
    Thakuria, Manisha
    Bresler, Scott C.
    Sholl, Lynette M.
    Shapiro, Geoffrey I.
    Haddad, Robert
    DeCaprio, James A.
    ONCOLOGIST, 2018, 23 (07): : 814 - 821
  • [46] Characterization and survival benefit of drugs approved for advanced renal cell carcinoma.
    Benjamin, David Joseph
    Rezazadeh, Arash
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [47] Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2018, 34 (10) : 457 - 465
  • [48] Advanced Renal Cell Carcinoma Cabozantinib is a recommended Treatment Option for First-line Therapy
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (03) : 150 - 151
  • [49] Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
    Bergerot, Paulo
    Lamb, Peter
    Wang, Evelyn
    Pal, Sumanta K.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12) : 2185 - 2193
  • [50] Advanced Renal Cell Carcinoma Cabozantinib plus Nivolumab: New First-Line Standard?
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 362 - 363
12345